Back to News
Market Impact: 0.2
Barclays Initiates Coverage of Ligand Pharmaceuticals Incorporated - Equity Right at Overweight
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Barclays initiated coverage of Ligand Pharmaceuticals Incorporated Equity Right (OTCPK: LGNDZ) with an Overweight rating on September 25, 2026. The positive analyst action may support investor sentiment toward the security, though the article provides no price target, earnings revisions, or financial-performance details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
BCS0.10
More News
- CDs Are Paying 4%. Here's the One Scenario Where They Actually Make Sense
- Trump’s new Medicaid rules will kick in, and GOP states are tougher. Someone may be too frail to work but can’t afford to see a doctor to prove it
- Insurers claim AI is already increasing healthcare costs
- Hershey Trust Co. sells $5.05 million in Hershey Co. stock
- ‘Godfather of AI’ explains how humanity could end: Even without a bad actor, AI ‘may derive subgoals that cause it to want to get rid of people’
- Supply glut, lab-grown alternatives: What's behind the fall of diamond prices to record lows